Pioneering Treatments for Paroxysmal Nocturnal Hemoglobinuria

By Staff Writer

December 11, 2023

Introduction

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired blood disorder. It is characterised by chronic destruction of red blood cells and blood clots, primarily manifesting in fatigue and potentially leading to lifelong dependence on blood transfusions. The disease affects 10 to 20 people per million, primarily adults, with no association with sex, race, ethnicity, or geography. This Institute for Clinical and Economic Review (ICER) draft evidence report provides a comprehensive review of the latest research findings and treatments for PNH.

The Current State of PNH Treatment

The treatment landscape for PNH has been transformed by the advent of C5 inhibitor therapy. This treatment significantly reduces intravascular hemolysis, thrombosis, and death, bringing life expectancies closer to age-matched controls. FDA-approved intravenous C5 inhibitors, such as eculizumab and ravulizumab, are recommended for symptomatic PNH patients. Ravulizumab is often preferred due to its longer half-life and lower costs.

Pegcetacoplan – A New Hope

Pegcetacoplan, another FDA-approved treatment, has shown promise. Unlike C5 inhibitors, pegcetacoplan prevents both intra and extravascular hemolysis. However, it is largely used only for patients who have clinically significant extravascular hemolysis (EVH) while on a stable C5 inhibitor regimen.

Iptacopan and Danicopan – The Next Generation of PNH Treatments

Two first-in-class proximal complement inhibitors, Iptacopan and Danicopan, are currently under consideration for FDA approval. Iptacopan, an oral Factor B inhibitor, is being considered for all PNH patients, while Danicopan, an oral Factor D inhibitor, is being considered as an add-on therapy for treatment-experienced patients with clinically significant EVH. Both drugs display promising early trial results. However, we need more research to comprehend their long-term benefits and safety profiles fully. 

The Cost-Effectiveness of New Treatments

A recent study examined the cost-effectiveness of iptacopan and add-on danicopan in treatment-experienced patients with PNH. The study found that treatment with iptacopan resulted in small gains in quality-adjusted life years (QALYs) and equivalent life years (evLYs), and would be cost-saving compared to ravulizumab. However, treatment with add-on danicopan resulted in more costs, with an incremental cost-effectiveness ratio of $9,462,000 per QALY or evLY gained.

Conclusion

New therapies like iptacopan and danicopan are changing the treatment landscape for PNH, a rare blood disorder. We need to investigate their long-term benefits and safety profiles further. Their cost-effectiveness will depend on their price as per this ICER report.

Reference url

Recent Posts

Novo Nordisk performance
      

Business Dynamics: How Novo Nordisk Lost GLP-1 Market Share

🚀 Understand the market dynamics of Novo Nordisk’s GLP-1 Market Share Decline.

A case of demand underestimation, supply chain strain, and competitor agility. Using systems thinking, we unpack the dynamic forces behind Eli Lilly’s surge—and what strategic levers pharma leaders must pull to stay ahead.

#SyenzaNews #PharmaStrategy #MarketDynamics #NovoNordisk #EliLilly #GLP1

Tolebrutinib MS analysis
          

Tolebrutinib MS Analysis: Evaluating Economic Impact in SPMS

💡 Can tolebrutinib reshape the treatment landscape for progressive multiple sclerosis?

A recent report from the Institute for Clinical and Economic Review reveals promising insights on tolebrutinib, demonstrating a 31% reduction in disability progression for patients with non-relapsing secondary progressive MS. Yet, mixed outcomes and potential safety concerns raise critical questions about its long-term efficacy and market access.

Explore the nuances of this groundbreaking therapy and its implications for healthcare economics.

#SyenzaNews #HealthEconomics #MarketAccess

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.